Valuation: Precipio Inc

Market Cap 42.54M 37.21M 34.32M 31.7M 60.15M 4.06B 61.16M 410M 161M 2B 160M 156M 6.87B P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 43.54M 38.09M 35.13M 32.45M 61.56M 4.15B 62.6M 420M 165M 2.05B 163M 160M 7.03B EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.41%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 31/05/2017
Chief Executive Officer 54 27/06/2017
Director TitleAgeSince
Director/Board Member 54 27/06/2017
Director/Board Member 78 25/09/2017
Director/Board Member 67 07/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+20.04%-15.97% - - 42.54M
+3.73%+6.80%+9.75%-22.36% 17.28B
+3.87%-5.71%+14.03%+89.94% 1.68B
+4.76%+0.11%-39.78%-78.85% 1.25B
-2.75%-6.73%-32.28%+29.11% 1.06B
+2.92%-2.22%-29.25%-54.48% 626M
+3.91%-4.74%-39.86%-57.02% 555M
+2.60%+4.15%+35.25%-52.31% 466M
+1.13%-0.48%-54.86%-58.92% 380M
+2.67%-5.46%-24.37%-24.54% 342M
Average +4.29%-0.88%-17.93%-25.49% 2.63B
Weighted average by Cap. +3.44%+4.44%+2.33%-17.90%

Financials

2024 2025
Net sales 18.53M 16.21M 14.95M 13.81M 26.2M 1.77B 26.64M 179M 70.15M 871M 69.58M 68.07M 2.99B 24.05M 21.04M 19.4M 17.92M 34M 2.29B 34.58M 232M 91.04M 1.13B 90.3M 88.33M 3.88B
Net income -4.29M -3.75M -3.46M -3.2M -6.07M -409M -6.17M -41.35M -16.24M -202M -16.11M -15.76M -693M -363K -318K -293K -270K -513K -34.62M -522K -3.5M -1.37M -17.06M -1.36M -1.33M -58.63M
Net Debt -136K -119K -110K -101K -192K -12.97M -196K -1.31M -515K -6.39M -511K -500K -21.97M 1M 876K 808K 747K 1.42M 95.56M 1.44M 9.66M 3.79M 47.08M 3.76M 3.68M 162M
Logo Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-